Gene therapy for recessive dystrophic epidermolysis bullosa using genetically corrected autologous keratinocytes
US-12173314-B2 · Dec 24, 2024 · US
US12290613B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12290613-B2 |
| Application number | US-201213647308-A |
| Country | US |
| Kind code | B2 |
| Filing date | Oct 8, 2012 |
| Priority date | Oct 6, 2011 |
| Publication date | May 6, 2025 |
| Grant date | May 6, 2025 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
Described herein are compositions composed of micronized particles derived from one or more components present in placental tissue in combination with one or more bone grafts. The compositions have numerous medical applications. Methods for making and using the micronized compositions are also described herein.
Opening claim text (preview).
What is claimed: 1. A micronized placental composition comprising (a) dehydrated micronized particles, selected from the group consisting of micronized placental amnion particles and micronized particles comprising placental amnion and chorion, and (b) one or more bone grafts; wherein said dehydrated micronized particles comprise a fibroblast cell layer; wherein the one or more bone grafts are independently selected from the group consisting of an autograft, an allograft, a xenograft, and an alloplast, and any combination thereof; wherein the amount of said micronized particles to said one or more bone grafts is from 1:99 to 99:1 by volume. 2. The composition of claim 1 , said dehydrated micronized particles having a particle size of from 150 μm to 350 μm. 3. The composition of claim 1 , wherein the dehydrated micronized particles are 100% micronized placental amnion. 4. The composition of claim 1 , further comprising micronized Wharton's jelly. 5. A pharmaceutical composition prepared by admixing the composition of claim 1 with a pharmaceutically-acceptable carrier. 6. The composition of claim 5 , wherein the pharmaceutically acceptable carrier comprises water, saline, Ringer's solution, dextrose solution, Hank's solution, a buffer, or a nonaqueous vehicle. 7. The composition of claim 6 , wherein the buffer comprises a phosphate buffer, bicarbonate buffer, or Tris buffer. 8. The composition of claim 5 , wherein the pharmaceutically acceptable carrier comprises a biocompatible filler. 9. The composition of claim 8 , wherein the filler is carboxymethylcellulose, cellulose, hyaluronic acid or a salt thereof, glycerin, or any combination thereof. 10. The composition of claim 1 , wherein the composition is injectable. 11. The composition of claim 1 , wherein the composition is a foam, gel, putty, or paste. 12. A composition consisting essentially of: a. dehydrated micronized placental amnion particles, wherein the micronized placental amnion retains a non-viable fibroblast cell layer; and b. one or more bone grafts; wherein the one or more bone grafts are independently selected from the group consisting of an autograft, an allograft, a xenograft, and an alloplast, and any combination thereof; wherein the amount of the dehydrated micronized placental amnion particles to the one or more bone grafts is from 1:99 to 99:1 by volume. 13. A micronized composition suitable for use in treating a bone defect, the composition consisting essentially of: (a) dehydrated micronized placental amnion particles, wherein the micronized placental amnion retains a fibroblast cell layer; (b) one or more bone grafts; wherein the one or more bone grafts are independently selected from the group consisting of an autograft, an allograft, a xenograft, and an alloplast, and any combination thereof; (c) a pharmaceutically acceptable carrier admixed with (a) and (b), and (d) a biodegradable filler; wherein the amount of said dehydrated micronized placental amnion particles to said one or more bone grafts is from 1:99 to 99:1 by volume. 14. The micronized composition of claim 13 ; wherein the dehydrated micronized placental amnion particles have a particle size of from 150 μm to 350 μm. 15. The composition of claim 11 , wherein the composition is a foam.
Flowable or injectable implant compositions · CPC title
for joint reconstruction · CPC title
for reconstruction of bones; weight-bearing implants · CPC title
Bone, e.g. demineralised bone matrix [DBM], bone powder · CPC title
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.